Avai Bio, Inc.
AVAI BIO, INC. is a U.S.-based technology company that has evolved through several name changes, including Avant Technologies Inc. and Trend Innovations Holding Inc. The company describes its core focus as acquiring, creating, and developing AI-enabled technologies while also offering information technology consulting services. Its reported assets and initiatives include the Avant! AI text-generation system, a joint venture and license arrangement with Ainnova Tech, and software/data-service capabilities such as full-stack development, database management, data integration, project management, and cloud services. The company also previously owned a news-aggregation app through Thy News LLC and pursued technology asset acquisitions such as Wired4Health, although that transaction was later canceled. AVAI BIO is still in an early commercialization stage and has not yet generated meaningful revenue from its platforms.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueIncludes the Avant! AI system and other AI-related technologies the company acquires or develops.
Covers consulting, project management, and technology integration services for clients.
Includes cloud services, database management, and data integration capabilities.
Includes the Thy News news-aggregation application and related paid features.
Customers
The company’s customer base appears to be a mix of enterprise technology users, software and data-services clients, and potential users of its consumer-facing news application. Its IT consulting and infrastructure capabilities are aimed at organizations that need software development, database management, data integration, and cloud support. The Avant! AI platform is positioned for customers seeking AI-enabled automation or text-generation capabilities, although the company has not yet demonstrated broad commercial traction. The Thy News app serves individual consumers who want customizable news feeds and may pay for enhanced functionality. Because AVAI BIO is still early-stage, customer demand remains more prospective than recurring.
Buy software development, database, integration, and cloud services to support internal systems and projects.
Adopt or license Avant! AI-related capabilities for text generation and AI workflow use cases.
Use the Thy News application for customizable news feeds and potential paid premium features.
Provide technology assets, licenses, or development rights that the company uses to build its product base.
Strategy
The company’s strategy is centered on building an AI-oriented technology portfolio through acquisitions, licensing, and internal development. Management emphasizes turning acquired assets such as Avant! AI into commercial products and services that can be sold to customers, while also using consulting and cloud capabilities to broaden the offering. A second strategic theme is assembling technology resources through joint ventures and asset purchases, which can accelerate product development without building everything in-house. The company also appears to be trying to preserve optionality across both enterprise software and consumer digital products. Execution risk remains high because the company must convert these assets into repeatable revenue while operating with limited capital and a short operating history.
The company needs to turn acquired AI assets into revenue-generating products to validate its business model.
Services can provide near-term customer relationships and potentially fund product development.
The company is building capability through external assets rather than only organic R&D.
A scalable platform is necessary to support growth without proportionate cost increases.
Geography
AVAI BIO is headquartered in the United States operationally, with a virtual office in Las Vegas, Nevada, while its registered office is in Vilnius, Lithuania. The company’s filings do not disclose meaningful country-by-country revenue, and it reported no revenue in the periods cited. Its business model is therefore not yet tied to a mature geographic sales footprint, but its corporate structure suggests a cross-border setup for administration and legal registration. Because the company is still pre-commercial, geography matters more for where it is incorporated and managed than for where it sells at scale. Any future expansion would likely depend on where it can commercialize AI software, consulting, or app products first.
Risks
AVAI BIO faces the classic risks of an early-stage technology company: limited operating history, uncertain product-market fit, and dependence on external financing. The company explicitly warns that it may be unable to commercialize acquired technologies such as Avant! AI or generate revenue from its platforms, which makes execution risk central to the investment case. It also reports weaknesses in internal controls and reliance on outside consultants, increasing the risk of reporting errors or governance issues. Because the business depends on acquisitions and technology integration, failed deals or poor assimilation could delay product launches and waste capital. More broadly, AI and software markets are fast-moving and competitive, so the company must keep pace with changing customer expectations, technical standards, and funding conditions.
- Limited operating history and start-up execution riskImpact: HighLikelihood: High
The company has little revenue history and is still building its business model, making forecasting and scaling difficult.
Exposure: All operations
- Inability to commercialize acquired technologiesImpact: HighLikelihood: High
Management states that Avant! AI and other acquired assets may not generate revenue despite investment.
Exposure: AI platforms and digital assets
- Dependence on external financingImpact: HighLikelihood: High
The company relies on equity and convertible debt to fund operations, which can be dilutive and restrictive.
Exposure: Corporate funding
- Internal control and reporting weaknessesImpact: MediumLikelihood: High
Disclosure controls were reported as not effective due to limited resources and reliance on consultants.
Exposure: Financial reporting
- Acquisition and integration riskImpact: MediumLikelihood: High
The strategy depends on acquiring and assimilating technology assets, which can fail or create delays.
Exposure: M&A and product development
Accounting
Judgemental itemsFuture service and software contracts will need clear performance obligations and timing of recognition.
Impact: Could affect when revenue is reported and how quarterly results fluctuate
Technology assets acquired through APAs and licenses may need fair value allocation and impairment testing.
Impact: Could materially change asset values and earnings
Financing structures may include embedded features, conversion terms, and equity classification judgments.
Impact: Could affect dilution, liabilities, and non-cash charges
Limited history increases uncertainty around assumptions used in financial reporting.
Impact: Could cause volatility in reported expenses and asset values
Similar listed companies
Publicly listed companies with a comparable business focus.
Anvi Global Holdings, Inc.
ANVI · Retail-Food Stores
AIFU Inc.
AIFU · Insurance Agents, Brokers & Service
AI Technology Group Inc.
Motors & Generators
Advanced Biomed Inc.
ADVB · Services-Medical Laboratories
Hestia Insight Inc.
HSTA · Services-Management Consulting Services
Eventiko Inc.
EVTK · Services-Miscellaneous Amusement & Recreation
Last updated: 24/09/2026